ArticleCancer discovery2025
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.
Abstract read
In one paragraph
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Breaking the immune "cold niche" in bone metastasis: core mechanisms of the multidimensional interwoven regulatory network and precision breakthrough strategies.Molecular cancer · 2026Review
- Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.Nature communications · 2026Article
- Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling.bioRxiv : the preprint server for biology · 2026Article
- Review
- Acquired HER2 expression promotes secondary metastasis in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Circulating tumor cells in breast cancer bone metastasis: mechanisms, clinical relevance, and future directions.Cell death discovery · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Rahat Alam *Icahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0001-9415-9386
Anna Reva *Icahn School of Medicine, Mount Sinai, New York, New York.ORCID 0009-0008-6300-4726
David G EdwardsLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-8002-0607
Bree M LegeLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-5009-4143
Laura S Munoz-ArcosDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0229-9056
Carolina ReduzziDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-0514-0152
Swarnima SinghIcahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0002-0923-268X
Xiaoxin HaoLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-8763-3529
Yi-Hsuan WuLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-7568-3948
Zeru TianDepartment of Chemistry, Rice University, Houston, Texas.ORCID 0000-0002-0437-2632
Laura M NataleeDan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0009-0002-8355-2355
Gargi DamleIcahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0001-6815-280X
Deniz DemirciogluIcahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0001-7857-0407
Yixian WangDepartment of Chemistry, Rice University, Houston, Texas.ORCID 0009-0004-3093-6835
Ling WuLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-5786-4315
Elisabetta MolteniDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0009-0005-1979-5020
Dan HassonIcahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0001-7943-1636
Bora LimDivision of Cancer Medicine, MD Anderson, Department of Breast Medical Oncology, Houston, Texas.ORCID 0000-0002-4182-6058
Zbigniew GugalaDepartment of Orthopedic Surgery and Rehabilitation, University of Texas Medical Branch, Galveston, Texas.ORCID 0000-0003-2331-7660
Jerry E ChipukIcahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0002-1337-842X
Julie E LangDivision of Breast Cancer, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-7534-6124
Joseph A SparanoIcahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0002-9031-2010
Chonghui ChengLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-5760-2008
Massimo CristofanilliDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-4194-7175
Han XiaoDepartment of Chemistry, Rice University, Houston, Texas.ORCID 0000-0002-4311-971X
Xiang H-F ZhangLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-5674-8670
Igor L BadoIcahn School of Medicine, Mount Sinai, New York, New York.ORCID 0000-0001-8855-4750
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MNIH FIRST Cohort Cluster Hiring Initiative at Icahn School of Medicine at Mount SinaiU54CA267776 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nihal Mohamed · 2021 to 2026
$17.4MOsteoclast-Independent Mechanisms of Early-Stage Bone Colonization of Breast CancerR01CA183878 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, XIANG · 2014 to 2024
$3.5MSpatiotemporal modeling of cancer-niche interactions in breast cancer bone metastasisU01CA253553 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WONG, STEPHEN TC, ZHANG, XIANG · 2020 to 2024
$3.0MUnveiling the mechanisms underlying secondary metastasis and possible therapeutic windowsR01CA251950 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, XIANG · 2020 to 2024
$2.6MChronic Mitochondrial Division and Melanoma: Mechanism, Prognosis, and TherapyR01CA267696 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jerry Edward Chipuk · 2022 to 2026
$2.4MThe Oncogene Activated Mitochondrial Unfolded Protein Response Regulates Senescence BiologyR01CA271346 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jerry Edward Chipuk · 2023 to 2026
$2.4MCOVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MFunction and Regulation of the BCL-2 FamilyR01CA237264 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHIPUK, JERRY EDWARD · 2020 to 2024
$1.9MTracing and targeting the epigenetic heterogeneity in breast cancer metastasisR00CA263033 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BADO, IGOR LANDRY · 2022 to 2024
$688kBreast Cancer Alliance (BCA)Breast Cancer Research Foundation (BCRF) 23-20-26-BADOCancer Prevention and Research Institute of Texas (CPRIT) CPRIT-RP180672Common Fund (NIH Common Fund) U54CA267776National Cancer Institute (NCI) K99CA263033-01A1National Cancer Institute (NCI) R01CA183878National Institutes of Health (NIH) P30CA196521NCI NIH HHS K99 CA263033NCI NIH HHS P30 CA125123NCI NIH HHS P30 CA196521NCI NIH HHS R00 CA263033NCI NIH HHS R01 CA183878NCI NIH HHS R01 CA237264NCI NIH HHS R01 CA251950NCI NIH HHS R01 CA267696NCI NIH HHS R01 CA271346NCI NIH HHS U01 CA253553NCI NIH HHS U54 CA267776NCRR NIH HHS S10 RR024574NIH HHS S10 OD018033NIH HHS S10 OD023469NIH HHS S10 OD025240NIH HHS S10 OD026880NIH HHS S10 OD030463U.S. Department of Defense (DOD) BC201371P1U.S. Department of Defense (DOD) W81XWH-21-1-0790
Abstract
significanceGiven the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2- breast cancer, which represents ∼70% of all cases.
Indexed as
Bone NeoplasmsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAnimalsBiomarkers, TumorCell Line, TumorFemaleHumansMiceNeoplasm MetastasisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.